Security key
01021M104
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 40,173
- Total 13F value
- $1,294,777
- Share change
- +40,173
- SEC-reported price per share
- $32.24
- Number of holders
- 3
- Value change
- +$1,294,777
- Number of buys
- 3
- Shares outstanding
- 53,432,253
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
3
Top holders
3
AKTS full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Aktis Oncology, Inc. SEC filings
Aktis Oncology, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 01021M104
Recent filing periods:
Ownership snapshot
Top reported holders of AKTS - Aktis Oncology, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
MPM BIOVENTURES 2018, L.P.
Disclosed value leader
MPM BIOVENTURES 2018, L.P.
Comparable rows
15/15
Latest evidence
31 Mar 2026
3/4/5
13D/G
13F
Lead comparable stake: 19%
13D/G row: MPM BIOVENTURES 2018, L.P.
Showing 1-6 of 15 holder rows.
Quick read
MPM BIOVENTURES 2018, L.P. leads the comparable SEC ownership view at 19%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens MPM BIOVENTURES 2018, L.P.'s linked filing trail.
Comparable ownership
Top 5
MPM BIOVENTURES 2018, L.P.
19%
ELI LILLY & Co
12%
VV Manager II, LLC
11%
EcoR1 Capital, LLC
9.1%
Blue Owl Capital Holdings LP
5.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| MPM BIOVENTURES 2018, L.P. |
3/4/5
13D/G
10%+ Owner · ANSBERT GADICKE
|
19%
from 13D/G
|
$219,052,366
10,260,064 shares
|
— | 12 Jan 2026 |
| ELI LILLY & Co |
3/4/5
13D/G
10%+ Owner · Eli Lilly and Company
|
12%
from 13D/G
|
$135,446,834
6,344,114 shares
|
— | 12 Jan 2026 |
| VV Manager II, LLC |
13D/G
Helen Kim
|
11%
|
—
5,831,315 shares
|
$0 | 12 Jan 2026 |
| EcoR1 Capital, LLC |
13F
13D/G
3/4/5
Company · Oleg Nodelman · Director
|
9.1%
from 13D/G
|
$86,309,750
4,824,469 shares
|
— | 31 Mar 2026 |
| Blue Owl Capital Holdings LP |
13F
13D/G
Company
|
5.9%
from 13D/G
|
$56,556,516
3,161,348 shares
|
— | 31 Mar 2026 |
| Ansbert Gadicke |
3/4/5
10%+ Owner
|
19%
|
$219,052,366
10,260,064 shares
|
— | 12 Jan 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
40,173
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
69
Q2 2026 holders
3
Holder diff
-66
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend